Citius Oncology Integrates Verix AI to Support Commercial Rollout of LYMPHIR for Rare T-Cell Lymphoma

Citius Oncology plans to integrate Verix AI into the commercial launch of LYMPHIR, its recently approved IL-2 receptor–directed fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Verix AI will support real-world patient identification, streamline specialty distribution workflows, and provide field teams with coordinated insights for clinician engagement. Citius says the platform is intended to improve speed-to-treatment in a rare cancer where diagnosis is often delayed and access pathways can be complex.

The move reflects a growing trend in oncology toward using AI to accelerate therapy adoption and improve care coordination. Verix’s focus on linking patient analytics with field operations provides a more integrated approach. For health systems, the combination of LYMPHIR and Verix AI could improve identification of eligible CTCL patients—a population often managed across dermatology and oncology clinics with inconsistent data visibility.

Posted by MedCloudInsider Editors on 11/24/2025